Standards & Regulation

Most, but not all, UK pharma companies are on track to keep their medicines on the European market by March, 2019.

Thought that most companies understood good manufacturing practice? Think again – there are always a few bad eggs.

China is upping its game with plans to revolutionize its manufacturing industries, including pharma.

The end of “mini me” medicine is over, says Andrew Parker, because we can do better when it comes to pediatric care.

Tommy Fanning believes that Ireland’s pharma industry will continue to thrive, despite tax cuts in the US and Brexit.

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Serialization deadlines will shortly be upon us – but, rather than entering into a blind panic, consider the long term.

Regulators step in to stop stem cell clinics from marketing unproven therapies.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Collaboration is crucial for supply continuity and control.